



September 19, 2017
NWMI-LTR-2017-014

U.S. Nuclear Regulatory Commission
ATTN: Document Control Desk
11555 Rockville Pike
Washington, DC 20555

Mr. Michael Balazik
Research and Test Reactors Branch A
Division of Policy and Rulemaking
Office of Nuclear Reactor Regulation

**RE: Northwest Medical Isotopes, LLC Response to U.S. Nuclear Regulatory Commission
Request for Additional Information Regarding Application for Construction Permit
(TAC No. MF6138), Docket No. 50-609, dated September 18, 2017**

References:

1. Email from Michael Balazik, U.S. Nuclear Regulatory Commission, to Carolyn Haass, Northwest Medical Isotopes, LLC, dated September 18, 2017, "Draft RAs Criticality"
2. Northwest Medical Isotopes, LLC Letter NWMI-LTR-2017-012 to U.S. Nuclear Regulatory Commission, dated September 8, 2017, "Docket No. 50-609, Northwest Medical Isotopes, LLC, Transmittal of Revision 3 of Chapters 1.0 through 18.0 of NWMI-2013-021, *Construction Permit Application for Radioisotope Production*"

Dear Mr. Balazik:

Northwest Medical Isotopes, LLC (NWMI) is providing the attached response (Attachment 1) to the U.S. Nuclear Regulatory Commission request for additional information dated September 18, 2017.

NWMI is submitting this response to the NRC in accordance with 10 CFR 50.30(b), "Oath or Affirmation," and 10 CFR 50.4, "Written Communications."


I solemnly declare and affirm that the foregoing information is true and correct under the penalty of perjury; executed on September 19, 2017.

YG01
NRR

Mr. Michael Balazik
page 2

If you have questions, I can be reached at (509) 430-6921 or carolyn.haass@nwmedicalisotopes.com.

Sincerely,



Carolyn C. Haass
Chief Operating Officer

Enclosures: Attachment 1

cc: Mr. Alexander Adams
Research and Test Reactors Branch A
Office of Nuclear Reactor Regulation